Recruiting
A Study Investigating the Utilization, Effectiveness and Quality of Life in Clinical Practice in Germany for Participants With Relapsing-remitting Multiple Sclerosis Treated With Ozanimod (Zeposia®)
The purpose of this study is to collect real-world data and to gain insights about long-term usage of ozanimod (Zeposia ®), its effect on well-defined outcome parameters comprising participant-relevant outcomes, as well as quality of life, effectiveness, and incidence of adverse events.
Inclusion Criteria: - Confirmed diagnosis of relapsing-remitting multiple sclerosis (RRMS) - The decision upon treatment with ozanimod must have been made before enrollment and independently of this non-interventional observational study - All data on ozanimod treatment are collected prospectively. The retrospective documentation of ozanimod therapy and enrollment of participants that are already on ozanimod therapy is not allowed Exclusion Criteria: - Special warnings, precautions and contraindications specified in the current version of the Summary of Product Characteristics (SmPC) - Hypersensitivity to the active substance(s) or to any of the excipients of ozanimod as specified in the prescribing information must not be enrolled - Participation in any other clinical studies Other protocol-defined inclusion/exclusion criteria apply
Participants with relapsing-remitting multiple sclerosis (RRMS) treated with Ozanimod
